samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CPI to showcase results from BioStreamline project developing novel biotherapeutics

Sphere Fluidics


CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.

The biopharmaceutical industry requires a more efficient supply chain that enables it to make predictions about the problems associated with developing novel biotherapeutics and to help reduce the risk and cost of commercialisation. This has the potential to offer patients access to a wider range of affordable and effective drugs by limiting the amount of resources wasted on unsuitable molecules. The BioStreamline project mitigates these biotherapeutic development challenges, offering a unique approach that uses state-of-the-art technologies to provide developers with a better understanding of candidate molecules earlier in the development process. The outputs of the BioStreamline project should allow developers to make better informed decisions about which molecules to progress, to address currently unmet medical needs.

BioStreamline is a collaborative project which brings together complementary assets and cutting-edge expertise from six partner organisations across the spectrum of drug discovery and development, with funding from the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI). The six partners were Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI.

The project involved the following major areas:

  1. The development of Sphere Fluidics’ novel single cell analysis and monoclonality assurance system (Cyto-Mine®) and associated methodologies. This enables the screening and isolation of valuable, rare B cells for antibody discovery and high-expressing single cells for cell line development, helping to increase the speed and efficiency of entry into the biologics supply chain.
  2. Investigating new approaches to cell line development by using Horizon’s CRISPR gene editing expertise to create cell lines that display specific phenotypes, including increased productivity.
  3. Collecting developability data derived from an initial set of over 200 monoclonal antibody sequences, down-selected to a defined panel of 50+ monoclonal antibodies. These antibodies are produced, purified and analysed, and biochemical, biophysical and stability data on the molecules collected, which is then used together with other inputs to create an agile, flexible and improved approach to biotherapeutics developability. Preclinical assessment of the immunogenicity risks of biotherapeutics, to minimise exposure of human patients to potential safety risks during early clinical trial development.
John Liddell, Chief Technologist, CPI, said: ​“We are very excited by the success of the project and feel that a similar approach could be used with other therapeutics, such as viral vectors, which are rapidly emerging as major therapeutic areas. The level of investment that AMSCI has made to this area has provided sufficient breadth of scope to increase understanding of this important aspect of biotherapeutic development, and we are looking forward to presenting the outcomes at the event later this month.

Register for the event or please or contact Helen Anderson for more information.
phone +44 1223 804200
email info@spherefluidics.com
web www.spherefluidics.com
email The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Aptar CSP’s Technologies Activ-Film™ Technology Protects New At-Home Prescription and OTC COVID-19 Tests

Auburn, AL, April 28, 2021 – Aptar CSP Technologies, a leader in material science and active packaging solutions (part of AptarGroup, Inc.), announced its Activ-FilmTM technology protects two new at-home COVID-19 tests that recently received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
More info >>


White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement